Skip to main content

“The acceptance of an accelerated regulatory review for leniolisib underlines the high unmet need for patients with APDS, with the product potentially being the first approved treatment for this rare disease."

- Anurag Relan - Chief Medical Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline